title: Olfactory toxicity of methimazole: dose-response and structure-activity studies and characterization of flavin-containing monooxygenase activity in the Long-Evans rat olfactory mucosa.
abstract: Methimazole is a compound administered to humans for the treatment of hyperthyroidism and is used experimentally as a model substrate for the flavin-containing monooxygenase (FMO) system. Previous results from this laboratory demonstrated that methimazole is an olfactory system toxicant, causing nearly complete destruction of the olfactory epithelium in the male Long-Evans rat following a single ip dose of 300 mg/kg. The present studies were undertaken to determine the dose-response relationship for methimazole-induced olfactory mucosal damage and to determine whether or not similar damage occurs as a result of oral administration, mimicking the relevant route of human exposure. We also investigated the mechanism of olfactory toxicity of methimazole by means of a structure-activity study and began the characterization of the form(s) of FMO present in the olfactory mucosa of the male Long-Evans rat. Dose-response analysis demonstrated that methimazole causes olfactory mucosal damage at doses of 25 mg/kg ip and greater. The results of gavage studies showed that a single oral dose of 50 mg/kg also caused olfactory mucosal damage. Two structurally related compounds, methylimidazole and methylpyrrole, were not olfactory toxicants, suggesting that a reactive intermediate generated in the course of metabolizing methimazole to an S-oxide is the olfactory toxic species. Microsomal incubation studies revealed the presence of methimazole S-oxidation activity in olfactory mucosal microsomes at levels comparable to those in liver. An anti-mouse liver FMO antibody reacted on Western blots with olfactory mucosal microsomes. These findings demonstrate a dose-response for the olfactory toxicity of methimazole and suggest that characterization of human olfactory mucosal FMO activity may be necessary to assess the potential for human risk associated with therapeutic exposure to methimazole.
authors.affiliation: Department of Toxicology, North Carolina State University, Raleigh 27695-7633, USA.
authors.forename: M B
authors.initials: MB
authors.lastname: Genter
authors.forename: N J
authors.initials: NJ
authors.lastname: Deamer
authors.forename: B L
authors.initials: BL
authors.lastname: Blake
authors.forename: D S
authors.initials: DS
authors.lastname: Wesley
authors.forename: P E
authors.initials: PE
authors.lastname: Levi
mesh_terms: D000284:Administration, Oral; D000818:Animals; D013956:Antithyroid Agents / Q000633:toxicity*; D015153:Blotting, Western; D004305:Dose-Response Relationship, Drug; D008297:Male; D008713:Methimazole / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000633:toxicity*; D008861:Microsomes / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D009831:Olfactory Mucosa / Q000187:drug effects* / Q000201:enzymology* / Q000473:pathology; D010105:Oxygenases / Q000737:chemistry*; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship
chemical_list: D013956:Antithyroid Agents; D008713:Methimazole; D010105:Oxygenases; C020066:dimethylaniline monooxygenase (N-oxide forming)